港股异动 | 获投行唱好 创科实业(0669.HK)涨逾4%再创新高
格隆汇4月8日丨创科实业(0669.HK)盘中直线拉升,最高见141港元续创新高,现报139.7港元,涨幅4.3%,最新总市值2560.45亿港元。美银证券指,公司是最具吸引力的长期增长股之一,而且公司正积极扩张,冀于5年内将公司规模增大一倍,进一步抛离竞争对手。凭借独一无二的新产品供应,美国消费者准备花费以及潜在的基础设施刺激,该行认为创科又将迎来辉煌的一年。该行重申“买入”评级,目标价由140港元升至157港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.